Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

Jan A. Burgera Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information

Tadeusz Robakb Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland

Carol Morenoe Hospital de la Santa Creu I Sant Pau, Autonomous University of Barcelona, Barcelona, SpainView further author information

Talha Munirg Department of Haematology, St. James’s Hospital, Leeds, United KingdomView further author information

Don A. Stevensh Norton Cancer Institute, Louisville, KY, USAView further author information

Sandra Daii Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information

Leo W. K. Cheungi Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information

Kevin Kweii Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information

Indu Lali Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information

Emily Hsui Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information

Thomas J. Kippsj University of California San Diego, Moores Cancer Center, La Jolla, CA, USAView further author information

Alessandra Tedeschik ASST Grande Ospedale Metropolitano Niguarda, Milan, ItalyView further author information

Your download is now in progress and you may close this window